EMA Authorised: Zolgensma (onasemnogene abeparvovec) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorises Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy under a conditional approval as an orphan medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Status: Authorised. Therapeutic area: Muscular Atrophy, Spinal. MAH: Novartis Europharm Limited. Decision date: 12/06/2026. Conditional approval. Orphan medicine